9% of cases underwent postmortem neuropathological examination. Our goal was to estimate the accuracy of the clinical diagnosis of parkinsonism and to assess the clinical phenotypes and characteristics of the discrepant patients in our pathological series.
Methods Case Identification
We used the medical records-linkage system of the Rochester Epidemiology Project (REP) to ascertain all incident cases of parkinsonism in Olmsted County, Minnesota, from 1991 to 2010. 6 Details regarding the identification of cases and the clinical diagnostic criteria are reported elsewhere. 5, 6 The Mayo Clinic Institutional Review Board approved this study, and participating patients (or their legally authorized representatives) provided written consent to use medical information. In brief, the clinical diagnosis of "parkinsonism" was defined as the presence of at least 2 of the following 4 cardinal signs: resting tremor, rigidity, bradykinesia, and postural instability. Among the patients who fulfilled the criteria for parkinsonism, we applied specific diagnostic criteria to classify the clinical subtypes of parkinsonism including PD, [4] [5] [6] progressive supranuclear palsy (PSP), 6, 7 Lewy body dementia (DLB), 8 Parkinson's disease with dementia, 5 corticobasal syndrome, 9 multiple system atrophy (MSA), 10 vascular parkinsonism, 11 and drug-induced parkinsonism. 12 Patients were clinically diagnosed with unspecified parkinsonism when they had insufficient clinical documentation to determine the diagnosis or if they did not meet any of these clinical criteria. 5 Dementia was only considered present if the physician made that diagnosis and it was recorded in the medical records. All of the cases were reviewed and received the final clinical diagnosis from a movement disorders specialist (R.S.). 5 
Pathological Diagnosis
Among the 669 patients identified with a clinical diagnosis of parkinsonism, 60 (9%) underwent autopsy. Data on the incidence, demographic, and clinical characteristics of the different parkinsonisms are reported elsewhere. 5, 12, 13 The most recent cohort study including data about the distribution of subtypes of parkinsonism from the same area included 542 patients. 5 In addition to those, our cohort included 127 extra cases because we extended our case collections to 2010; the distribution of the different subtypes of parkinsonism in our cohort did not differ significantly from the one observed in the previous study. Neuropathological characterization of the cases was made according to published neuropathological criteria [14] [15] [16] [17] [18] based on the presence of the pathological proteins (a-synuclein, tau, amyloid-b). 19 Additional details are described later.
Lewy Bodies Diseases
The presence of Lewy bodies (LBs) is a required pathological feature for the diagnosis of a Lewy body spectrum disorder (PD, DLB, and Parkinson's disease with dementia). [20] [21] [22] According to the initial consensus pathologic guidelines, we used the anatomical distribution of LBs to differentiate brain stem predominant, limbic/transitional, and neocortical types (DLB). 15 
Tauopathies
The tau protein belongs to the family of microtubule-associated proteins, and it is typically expressed in healthy human neurons 23 but also in oligodendrocytes and astrocytes, 24, 25 where it becomes particularly important under pathological conditions. The 4-repeated isoform of tau accumulates in astrocytes ("tufted astrocytes") and in oligodendroglia ("coiled bodies") in PSP, whereas astrocytic plaques and ballooned neurons are hallmarks of corticobasal degeneration (CBD). 26 Neuronal accumulation of hyper-phosphorylated tau characterizes neurofibrillary pathological features of AD 27, 28 and primary agerelated tauopathy (PART). 29 
Alzheimer's Disease
We used the presence of cerebral senile plaques and neurofibrillary tangles (NFT) to confirm the diagnosis of AD using all of the following 3 pathological criteria commonly used to assess the diagnosis of AD: Braak criteria, 30 Consortium to Establish a Registry for Alzheimer's Disease criterion, 31 and the National Institute of the Alzheimer's Association criterion. 14 
Statistical Analysis
We ascertained the clinical diagnosis by reviewing clinical records of each patient with focus on the last clinical diagnosis made by a movement disorders specialist (R.S.) and recorded in the medical records. Then we compared the clinical diagnosis with the pathological diagnosis by the neuropathologist. The pathological diagnosis was considered the "gold standard" to determine the final diagnosis for each patient. The diagnostic measures, including sensitivity, positive predictive value (PPV), and accuracy, were calculated.
Results
We previously identified 669 incident cases of parkinsonism in Olmsted County, Minnesota, from 1991 to 2010. 5 Among these 669 cases, 60 (9%) underwent autopsy. When compared with patients who did not undergo autopsy, autopsied patients did not differ with regard to sex, age at diagnosis, or age at death (all P > .05). The median age at death for these 60 autopsied patients was 83 years (range 56-99 years), and the median time from the last clinical diagnosis recorded in the medical records to death was 7 years (range 2-17 years). The median time between the last neurological visit and death was 1.8 years (range 1 month to 13 years). The median Hoehn & Yahr scale score at the final visit prior to death was 4 (range 2-5).
Clinical-Pathological Agreement
The sensitivity for the whole group of patients with a pathological confirmation of LB-related diseases (PD and DLB) clinically diagnosed correctly was 100%. PPV was 84.1%, and diagnostic accuracy was 88.3%. When we excluded from this group the 3 cases with a clinical diagnosis of unspecified parkinsonism, we reported a PPV of 85.7%, a sensitivity of 100%, and a diagnostic accuracy of 89.5%; we observed no false negative cases. For the clinical diagnosis of PD, PPV was 83.3% (20 of 24), sensitivity 100%, and accuracy 93.0%. For the clinical diagnosis of DLB, PPV was 88.9% (16 of 18), sensitivity was 100%, and accuracy was 96.5%. The PPV for the clinical diagnosis of MSA was 100% (5 of 5), 75% for PSP (3 of 4), and 100% for CBD (1 of 1).
Clinical-Pathological Characteristics
Of the 60 parkinsonian patients who underwent autopsy, 37 (61.7%) patients had a pathological diagnosis of a Lewy Body spectrum disorder (LBD); 5 (8.3%) had a pathological diagnosis of MSA; 4 patients (6.7%) had a pathological diagnosis of PSP; 5 (8.3%) had a pathological diagnosis of vascular parkinsonism. In addition, 5 (8.3%) patients had a pathological diagnosis of AD, 1 (1.6%) of CBD, 1 (1.6%) of PART, and 1 (1.6%) unspecified pathological diagnosis. We also observed 1 (1.6%) case with no pathological findings but a clinical diagnosis of druginduced parkinsonism.
Among the 37 patients with a pathological diagnosis of LBD, 16 (43.2%) were clinically diagnosed as DLB, 20 (54.1%) with PD, and 1 with unspecified parkinsonism. Among the LBD cases, 25 (67.6%) had neocortical-type LBD, 11 had limbic type, and 1 was brain stem predominant. Of the 25 patients with neocortical LBD, 15 (60.0%) had hallucinations, and 19 (76.0%) had a clinical diagnosis of dementia. Of the 11 patients with limbic-type LBD, 3 (27.2%) had hallucinations and 5 (45.5%) had dementia. Of the 37 patients with a pathological diagnosis of LBD, 30 patients (81.0%) were treated with L-dopa or dopamine agonists, 19 (63.3%) of which showed a welldocumented response to the therapy. A total of 5 patients (16.6%) had clinically documented dysautonomia (orthostatic hypotension).
There were 5 pathological cases of MSA, and all had a concordant clinical diagnosis. Of the 5 patients with MSA, none had documented L-dopa responsiveness, 2 had ataxia, and 2 had mild upward gaze limitations.
One patient had a clinical and pathological diagnosis of corticobasal syndrome/CBD with clinical characteristics consistent with the diagnosis of corticobasal syndrome (parkinsonian symptoms with bilateral involvement, visual and auditory hallucinations, paranoia, and dementia, asymmetrical reflexes, dysexecutive dysfunction, normal eye movement, prominent grasp reflexes, and unilateral apraxia).
PSP was pathologically diagnosed in 4 cases. One patient had both PSP and LBD limbic predominant type and was clinically diagnosed with PSP. Two patients had a clinical diagnosis of PSP including the one with LBD comorbidity, 1 had PD, and 1 had unspecified parkinsonism. Among these 4 patients, 1 showed upward gaze limitations, 1 showed a skew deviation with diplopia (both vertical and horizontal), 1 had an eyelid apraxia without gaze limitation, and 1 patient had both upward and downward gaze limitations. The 2 patients with a concordant clinical-pathological diagnosis of PSP also reported frequent falls and a poor response to L-dopa.
A total of 5 patients had a pathological diagnosis of vascular parkinsonism. Of these patients, 4 (80%) had a clinical-pathological correspondence for the diagnosis, whereas 1 case was clinically diagnosed with idiopathic PD. In all of these cases, there was clear documentation of rapid-onset symptoms after a documented acute cerebrovascular event and a stepwise progression. One case showed only mild pigmentary incontinence of the substantia nigra (sn).
A total of 5 patients had a pathological diagnosis of AD without a corresponding clinical diagnosis (clinical diagnoses: 2 DLB, 2 PD, 1 unspecified parkinsonism). All 5 had dementia and showed parkinsonian symptoms, but only 1 responded to L-dopa.
We observed a case with a pathological diagnosis of LBD, showing a 9-year disease duration and clinical findings of dementia, upward gaze limitations, and bilateral rest tremor; 1 had a pathological diagnosis of advanced AD with dementia, bilateral resting tremor, cogwheel rigidity, and bradykinesia; 1 had a pathological diagnosis of PSP, showing a bilateral tremor at rest, right-sided bradykinesia and rigidity, skew deviation of the eyes with diplopia, and reduced abduction. In all of these cases, the given clinical diagnosis was unspecified parkinsonism. In addition, there was 1 case of PART with a clinical diagnosis of unspecified parkinsonism and 1 case with unspecified pathological diagnosis with a clinical diagnosis of PSP. Only 1 patient was clinically diagnosed with drug-induced parkinsonism as a result of the previous administration of antipsychotic drugs (trifluoperazine and risperidone).
The clinical-pathological characteristics of the 52 concordant cases are reported in Table 1 . 
Discrepancies
Among 60 patients that underwent autopsy, 8 cases (13.3%) had a clinical-pathological discrepancy. The median time from diagnosis to death was 5 years (range 2-9 years). The clinical and pathological characteristics of the 8 discrepant cases are reported in Table 2 . All the clinical diagnoses were confirmed by a movement disorders specialist (R.S.), who reviewed the entire medical record of each patient. Of the 8 cases, 4 had a clinical diagnosis of PD; none had the pathological presence of LBs or a-synuclein.
Case 1 had a clinical diagnosis of PD that responded to L-dopa treatment. The pathological diagnosis was vascular parkinsonism with only mild pigmentary incontinence of sn and diffuse neocortical and subcortical b-amyloid plaques. No head MRI was performed for this patient. The head CT scan performed at the time of the initial diagnosis revealed only physiologic calcifications within the basal ganglia and a small lacuna involving the genu of the left internal capsule.
Case 2 had a clinical diagnosis of PD with mild cognitive impairment, whereas the pathological diagnosis was AD, with mild pigmentary incontinence of sn and cortical and subcortical diffuse b-amyloid deposits.
Case 3 had a clinical diagnosis of PD without the presence of any atypical features. The pathological exam showed only mild pallor of sn; b-amyloid plaques in the entorhinal cortex, subiculum, hippocampus, and in the endplate; tau deposits in many structures as well as the sn, subthalamic nucleus, globus pallidus, cerebellar dentate nucleus, and neocortical areas. A pathological diagnosis of PSP was given for this patient.
For case 4, the clinical diagnosis was PD without cognitive impairment, and the pathological diagnosis was AD with frequent cortical and subcortical neuritic plaques and NFT and only mild pigmentary incontinence of sn without significant neuronal loss or gliosis.
For cases 5 and 6, the clinical diagnosis was DLB, but no LBs or a-synuclein deposits were found during the autopsy. Pathological diagnosis was AD for both (Braak stage VI; National Institute of the Alzheimer's Association criterion: high likelihood) with the presence of diffuse cortical and subcortical b-plaques and NFT. Both of them had mild pigmentary incontinence with no significant neuronal loss in sn and locus coeruleus.
Case 7 had a clinical diagnosis of PSP but an indeterminate pathological diagnosis. There was no evidence of a-synuclein, tau, or b-amyloid deposits, but interestingly the patient had clinical features of dementia, supranuclear gaze limitations, and signs of dysautonomia (urinary incontinence). In addition, there were other parkinsonian features likely caused by the administration of trifluoperazine for a concurrent diagnosis of bipolar disorder type I (bilateral resting tremor, frequent falls, and rigidity).
Case 8 had a clinical diagnosis of unspecified parkinsonism with a pathological diagnosis of AD, no 
T U R C A N O E T A L
LBs, and only nonspecific a-synuclein deposits limited to the amygdala.
Discussion
In the current era, brain autopsies have become infrequent, as evidenced by the 9% frequency in this population-based cohort. This is further reduced from the 17% brain autopsy frequency among cases of parkinsonism in our community in the 15 years prior to the current study interval. 6 As previously documented, 6 historically usually only individuals who donate their bodies or brains for research or who have atypical features undergo autopsy. However, in our series, the vast majority had a clinical diagnosis of LBD (20 cases clinically diagnosed as PD and 16 as DLB); thus, this general observation is not entirely true in our cohort, where we have a larger number of cases with PD and DLB. In our study, the final clinical diagnoses were consistent with the neuropathology approximately 87% of the time. We observed a high PPV for all patients with a clinical diagnosis of DLB (PD plus DLB) of 85.7% and an accuracy of 89.5% with a sensitivity of 100%. This suggests that the advances in imaging and other testing and improved clinical criteria in the current era better equip clinicians to identify the underlying pathology and make a correct diagnosis. In the past, a number of studies investigated the accuracy of clinical diagnosis of idiopathic PD and reported an accuracy of about 76% and 84%. [32] [33] [34] The advent of the United Kingdom Parkinson's Disease Society Brain Research Center Clinical Diagnostic Criteria for Idiopathic PD 35 provided an additional improvement of the clinic pathology concordance, showing an overall PPV of 85.3% for clinical diagnosis of parkinsonian syndromes, a PPV of 98.6% just for a clinical diagnosis of idiopathic PD, with a sensitivity of 91.1%. Most of these studies were based on a clinical series of tertiary centers; thus, they may be not representative of the general population of parkinsonism. In fact, even the United Kingdom Parkinson's Disease Society Brain Research Center are devoted to define only PD; however, little is known about the whole spectrum of parkinsonism; a recent study investigating the accuracy of the clinical diagnosis of MSA reported a diagnostic accuracy of 62%. 36 Our previous study using the data of 364 incident cases of parkinsonism reported a diagnostic sensitivity of 43.7% and an accuracy of 61.5%. 6 A recent metaanalysis reported that the accuracy of the clinical diagnosis of PD in the past 25 years has remained suboptimal. 37 The accumulation of a certain protein in specific areas of the brain is necessary for the definite diagnosis of most neurodegenerative diseases. The presence of LBs in brain, with a-synuclein as the major component, is the hallmark for the definite diagnosis of PD and DLB. [20] [21] [22] Further arguments in favor of a-synuclein accumulation as a marker of PD are a result of the link between a mutation in the a synuclein (SNCA) gene encoding for a-synuclein and the subsequent development of early-onset PD in familial cases. 38 On the other hand, the presence of LBs in brain autopsies to confirm the diagnosis of PD has been recently questioned. 33 Although LBs are found in more than 90% of patients with clinical diagnosis of PD in life, 35 they may not be present in certain genetic forms of PD; most cases of Parkinson's gene mutations [39] [40] [41] [42] do not seem to have LBs deposition. [43] [44] [45] [46] In our study, we reported an overall accuracy of 89.5% for the clinical diagnosis of LB-related diseases; in all of these cases, the clinical diagnosis was confirmed pathologically by the presence of LBs in specific areas of the brain. At the same time, some cases had a clinical diagnosis not supported by the pathological features. These findings suggest that LBs and asynuclein deposition play a major role in neurodegenerative processes, but are not sufficient to explain all cases. The clinical diagnoses in our cases were supported by the criteria, and there was no major evidence of atypical clinical features to change the diagnosis or confuse the clinicians. At times, the Ldopa was untreated because of the different clinical approaches adopted by the treating neurologist or per patient decision.
We hypothesized that other mechanisms account for patients with clinical features of parkinsonism and no LBs deposits. Parkinsonism may in fact represent a group of disorders with different primary mechanisms; LBs deposits may be the main mechanisms of the process, but other mechanisms may lead to the same outcomes from different biochemical patterns. 47 One of these mechanisms may be related to the known vulnerability of the dopaminergic neurons of the sn to mitochondrial insults. 48 Interestingly, deposits of NFTs in the sn may theoretically lead to the same clinical syndromes using a different protein-related process. In fact, 5 of our cases had pathology findings consistent with AD without having the symptoms associated to the clinical diagnosis of AD. Moreover, case 8 in our series had a clinical diagnosis of unspecified parkinsonism and a pathologically confirmed diagnosis of advanced AD with widespread neocortical b-amyloid plaques and NFT but only nonspecific a-synuclein deposits limited to amygdala. This patient showed clinical features of dementia and parkinsonian symptoms but, interestingly, no visual hallucinations. 49 Amygdala LBs are not uncommon in AD, 50 but the clinical significance of these findings is unknown. On the other hand, it is also possible that age-related parkinsonism plays a role in
some of the cases with discrepant clinical-pathologic features. 51, 52 Furthermore, AD pathology coexists in DLB patients 53 (87 % 54 ). In contrast, AD pathology is only present in about 40% of PD patients. 55 Among the 37 pathologically confirmed DLB cases, we found 32 cases (86.5%) with diffuse b-amyloid plaques. These findings suggest a frequent coexistence of these 2 diseases and that there may be a common role for b-amyloid plaques and LBs in the development of dementia in DLB. The accumulation of LBs in LBrelated disorders is not sufficient to explain the developing of dementia in all the cases because some PD patients with a high neocortical LBs burden remain cognitively intact. 56 The co-occurrence of b-amyloid plaques and LBs is associated with a higher cognitive impairment, 57 and it is a better predictor of dementia compared with the accumulation of LBs or b-amyloid alone 56 ; DLB patients who show the presence of bamyloid deposition tend to develop a higher rate of brain atrophy with an AD-like pattern. 57 Moreover, a recent study reported that increasing severity of AD neuropathology in patients with LB-related diseases may lead to a narrower interval between the onset of motor symptoms and the development of dementia. 58 In light of these findings, we explored our cohort and among the 32 patients with b-amyloid in the brain autopsy, 18 (56.3%) were clinically diagnosed as demented. The median time between the onset of motor symptoms and the development of clinically diagnosed dementia was 1 year (range 0-7 years). One patient with a long clinical history of PD developed dementia after 14 years from the onset of the disease; the presence of AD neuropathological changes was described as "pathologic aging."
Although the neuropathological examination is still required for the definite diagnosis of neurodegenerative diseases, a number of factors can contribute to the results of pathology: aging of the population, overlapping symptoms shared by different disorders, extreme heterogeneity of some neurological diseases, and the well established presence of mixed pathology mostly in the late stages of the disease. In addition, the relatively low referral rate of patients with parkinsonism that come to autopsy and the possible different pathophysiological mechanisms underlining these diseases raise doubts as to whether the brain autopsy should be considered as the gold standard for the diagnosis of LB-related diseases. The lack of correlation between the pathological findings and clinical features in some cases referred to as incidental Lewy body disease further underline the importance of developing specific in vivo biomarkers not to incur in the complexity of some cases.
Our study has a number of strengths. First, we used the records-linked system of the REP to study a large, well-defined, population-based cohort of parkinsonism (669 patients). All of the medical facilities in Olmsted County, Minnesota, are included in the REP, and it is unlikely that Olmsted County patients would have been evaluated for parkinsonism at medical facilities outside the county. Second, the population-based nature of this series makes this study an improvement over other referral-based studies that suffer from patient-and autopsy-selection biases. Third, the median follow-up of 7 years from clinical diagnosis to death allowed us to strengthen our clinical diagnosis and to categorize every patient by type of parkinsonism. Fourth, the agreement between autopsy findings and clinical diagnoses was high, suggesting that the clinical diagnosis made by the physicians was accurate. Last, all of the autopsies were performed by the same group of board-certified neuropathologists who have long-standing training in the pathological diagnosis of these diseases.
Our study also has a number of limitations. First, given the small number of patients who underwent autopsy, we caution against overinterpreting our data. Second, most patients were seen by several physicians at different times, and the clinical findings were recorded as part of the routine clinical practice and not standardized for research. Therefore, we may have missed features that were not documented. Third, we had few patients with a clinical or pathological diagnoses of PSP, MSA, or CBD. Fourth, despite not having observed differences between the patients who underwent autopsy with the patients who did not, the subjects (or their legally authorized representatives) who agreed to donate their brains may have been at higher risk for an atypical or more severe disease; thus, we cannot completely exclude a referral bias.
In conclusion, the linear concept that parkinsonism and other neurodegenerative diseases are only a result of the accumulation of certain proteins in the brain cells is somehow incomplete; in fact, rare cases of parkinsonian syndrome may be associated with an unexpected series of protein deposition. Interestingly, we observed an overall good accuracy for the clinical diagnosis of parkinsonian syndrome; however, pathological confirmation is still necessary for the definitive diagnosis. Differential diagnoses between parkinsonisms still represent a challenge for physicians because of overlapping clinical and pathological characteristics, especially in the elderly. Improving the diagnostic accuracy of parkinsonisms can lead to better therapeutic decisions, prognosis, and outcomes for the patients.
